Evidence map›Paper›PMID 41277181›Full record

ArticleChembiochem : a European journal of chemical biology2025

Immobilized Enzymes for ABO-Independent Blood Cell Transfusions.

Christina Möller, Fabian Pohlschröder, Jan Wesche, Paula Schmiade, Merle Baselau, Kristian Wende, Berenika Stloukalová, Dominique Böttcher, Andreas Greinacher, Uwe T Bornscheuer and 2 more

Abstract read
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. From Donation to Innovation: New Blood-Derived Products.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026
    Review
  2. Immobilized Enzymes for ABO-Independent Blood Cell Transfusions.Chembiochem : a European journal of chemical biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Christina MöllerDepartment of Biotechnology and Enzyme Catalysis Institute of Biochemistry, University of Greifswald, Felix-Hausdorff-Straße 4, 17487, Greifswald, Germany.
Fabian PohlschröderInstitute of Transfusion Medicine University Medicine Greifswald, Fleischmannstraße 8, 17475, Greifswald, Germany.
Jan WescheInstitute of Transfusion Medicine University Medicine Greifswald, Fleischmannstraße 8, 17475, Greifswald, Germany.ORCID https://orcid.org/0000-0001-5025-7355
Paula SchmiadeInstitute of Transfusion Medicine University Medicine Greifswald, Fleischmannstraße 8, 17475, Greifswald, Germany.
Merle BaselauInstitute of Transfusion Medicine University Medicine Greifswald, Fleischmannstraße 8, 17475, Greifswald, Germany.
Kristian WendeLeibniz Institute for Plasma Science and Technology, Felix-Hausdorff-Straße 2, 17489, Greifswald, Germany.ORCID https://orcid.org/0000-0001-5217-0683
Berenika StloukalováDepartment of Biotechnology and Enzyme Catalysis Institute of Biochemistry, University of Greifswald, Felix-Hausdorff-Straße 4, 17487, Greifswald, Germany.
Dominique BöttcherDepartment of Biotechnology and Enzyme Catalysis Institute of Biochemistry, University of Greifswald, Felix-Hausdorff-Straße 4, 17487, Greifswald, Germany.
Andreas GreinacherInstitute of Transfusion Medicine University Medicine Greifswald, Fleischmannstraße 8, 17475, Greifswald, Germany.ORCID https://orcid.org/0000-0001-8343-7336
Uwe T BornscheuerDepartment of Biotechnology and Enzyme Catalysis Institute of Biochemistry, University of Greifswald, Felix-Hausdorff-Straße 4, 17487, Greifswald, Germany.
Henrik TerholsenDepartment of Biotechnology and Enzyme Catalysis Institute of Biochemistry, University of Greifswald, Felix-Hausdorff-Straße 4, 17487, Greifswald, Germany.ORCID https://orcid.org/0000-0001-9625-8177
Konstanze AurichInstitute of Transfusion Medicine University Medicine Greifswald, Fleischmannstraße 8, 17475, Greifswald, Germany.ORCID https://orcid.org/0000-0003-3365-0168

Funding

German Research Foundation RTG2719
6 · The paper itself

Abstract

The transfusion of blood products requires ABO compatibility due to A and B antigens on blood cells and their corresponding antibodies in plasma. The supply of red cell concentrates (RCCs) and platelet concentrates (PCs) is challenged by rising demand and declining numbers of donors. To counteract the supply limitations, a method is developed to generate universal RCCs and PCs. For this, the A antigen is enzymatically removed by two enzymes from Flavonifractor plautii working in concert and the B antigen is removed by galactosidases from Pedobacter panaciterrae (PpaGal_WT or the variant PpaGal_W260Y) and Akkermansia muciniphila (AmGH110A or AmGH110B). The glycosidases are immobilized on polymethacrylate microparticles and are removed by the 200 µm filter of the mandatory transfusion set before the transfusion to avoid a possible immune reaction by the enzymes. B-positive red cells in RCCs are reduced below a 4% background signal within 48 h at 2-6 °C. Pooled PCs showed a 34 ± 14% reduction in B-positive cells and a residual A-positive platelet population of 4 ± 1% after 4 h of treatment at 20-24 °C. This approach efficiently generates ABO-universal RCCs and PCs while preserving blood quality and reducing incompatibility risks.

Indexed as

ABO Blood-Group SystemEnzymes, ImmobilizedGalactosidasesBlood PlateletsErythrocytesHumansABO Blood-Group SystemEnzymes, ImmobilizedGalactosidasesbiocatalysisblood type antigensenzyme immobilizationglycoside hydrolasesuniversal blood

Identifiers

PMID41277181
PMCPMC12703440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.